Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Crizotinib in ALK/ROS1/MET+ NSCLC
NCT03088930Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Dec 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by University of Colorado Denver. Started Dec 2017; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03088930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088930.